吉非替尼治疗晚期肺腺癌临床观察

The Clinical Observation of Gefitinib in Treating Advanced Adenocarcinoma of Lung

目的观察吉非替尼与多西他赛二线治疗晚期肺腺癌的疗效与毒副反应.方法 71例一线化疗失败的晚期肺腺癌患者,随机分为吉非替尼组和多西他赛组,吉非替尼组:250 mg,每天一次口服,维持治疗直至病情进展或出现不能耐受的不良反应.多西他赛组:75 mg/m2,第1天静脉滴注1 h,每21 d重复,至少接受2个疗程,评价其疗效及不良反应.结果 71例NSCLC均可评价疗效,2组总有效率(ORR)吉非替尼组40.0%(14/35),多西他赛组16.7%(6/36),P<0.05;疾病控制率(DCR)吉非替尼组74.3%(26/35),多西他赛组44.4%(16/36),P<0.05.吉非替尼组的毒性反应主要为皮疹和腹泻,多西他赛组主要存在骨髓抑制和胃肠道反应毒性(P<0.05).结论吉非替尼与多西他赛相比,治疗晚期肺腺癌有较好的有效性和安全性.

Objective To observe the curative and side effect of Gefitinib and Docetaxel as the second-line treatment for advanced adenocarcinoma of lung. Methods Atotal of 78 patients with advanced adenocarcinoma of Lung who had failed to previous firstline chemotherapy were randomly divided into two groups ： gefitinib group and docetaxel group.In the gefitinib group, patients were given orally 250 mg of gefitinib once daily, maintenance therapy until disease progression or patients could not tolerate the side effects.In the Docetaxel group, patient were given intravenous infusion of 75 rag/m^2 of Docetaxel, 1 hour intravenous infusion on the first day, the regimen was repeated every 21 days for at least 2 consecutive cycles. Then the curative and sideeffect was observed. Results AI the 71 ppatients could be evaluated. The overall response rate （eRR） of single agent Gefitinib group was 40.0% （14/35）, and that of combined Docetaxel group was 16.7% （6/36） ; the difference was significant （P 〈 0.05） The clinical disease control rate （DCR） of Gefitinib group was 68.6% （ 24/35）, and that of Docetaxel group was 55.6% （20/36） , the difference was significant （P 〈 0.05） reaction and bone marrow depression in Docetaxel group; The diarrhea. Conclusion Gefitinib compared with docetaxel Adenocarcinoma of Lung. The main toxicities included the alimentary tract main toxicities in Gefitinib group were skin rash and is more safe and effective in teating Advanced